Autoimmune Screening Panel

The Autoimmune Screening Panel panel contains 8 tests with 11 biomarkers .

A Comprehensive Evaluation for Systemic Autoimmune Disorders

The Autoimmune Screening Panel is a comprehensive blood test panel designed to evaluate markers commonly associated with systemic autoimmune diseases. Autoimmune conditions occur when the immune system mistakenly targets the body’s own tissues, leading to inflammation and potential organ involvement. Because symptoms of autoimmune disorders can be broad, overlapping, and sometimes nonspecific, a structured laboratory evaluation can provide important clinical insight.

This panel combines antinuclear antibody (ANA) testing with reflex titer and pattern analysis, disease-specific autoantibodies, complement protein levels, and Rheumatoid Factor. Together, these biomarkers help assess immune system activity and identify patterns associated with connective tissue diseases and systemic autoimmune conditions.

The ANA Screen by IFA (immunofluorescence assay) serves as a foundational test in autoimmune evaluation. When positive, reflex testing determines antibody titers and staining patterns, which may provide additional diagnostic clues. Disease-specific antibodies—including double-stranded DNA (dsDNA), SS-A (Ro), SS-B (La), Scl-70, RNP, and Sm antibodies—help evaluate for conditions such as systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, and mixed connective tissue disease.

Complement components C3, C4, and CH50 assess immune system activation and consumption, which may occur in certain autoimmune disorders. Rheumatoid Factor provides additional insight into inflammatory arthritis patterns.

By combining screening and confirmatory markers in one integrated panel, the Autoimmune Screening Panel supports a systematic, clinically relevant evaluation of autoimmune-related immune activity.

When and Why Someone Would Order This Panel

Evaluation of Unexplained Inflammatory or Systemic Symptoms

Individuals may consider the Autoimmune Screening Panel when experiencing symptoms that suggest possible immune system dysregulation. Autoimmune conditions can affect multiple organ systems and may present with joint pain, fatigue, rashes, dry eyes or mouth, muscle weakness, unexplained fevers, or other persistent inflammatory symptoms.

Because many autoimmune diseases share overlapping clinical features, laboratory testing plays an important role in narrowing the differential diagnosis. This panel is often used when healthcare providers are evaluating possible connective tissue disease or systemic autoimmune involvement.

Assessment of Connective Tissue Disorders

This panel may be appropriate for individuals undergoing evaluation for conditions such as:

• Systemic lupus erythematosus (SLE)

• Sjögren’s syndrome

• Systemic sclerosis (scleroderma)

• Mixed connective tissue disease (MCTD)

• Rheumatoid arthritis

The combination of ANA testing, disease-specific autoantibodies, complement levels, and Rheumatoid Factor helps provide a broader clinical picture.

Monitoring Known Autoimmune Conditions

For individuals with previously diagnosed autoimmune disorders, select markers within this panel—such as dsDNA antibodies or complement levels—may be used in monitoring disease activity or immune system trends over time. Changes in antibody levels or complement consumption can provide additional context in clinical decision-making.

Family History or Risk-Based Screening

Individuals with a family history of autoimmune disease may also undergo screening if symptoms arise. While laboratory testing alone does not diagnose autoimmune disease, it supports clinical evaluation and guides further investigation when appropriate.

This panel provides a structured starting point for evaluating systemic autoimmune conditions in a comprehensive and clinically meaningful way.

What Does the Panel Measure?

Antinuclear Antibody (ANA) Screen with Reflex

• ANA Screen by IFA: Detects antibodies directed against components of the cell nucleus.

• Reflex to Titer and Pattern: Determines antibody concentration (titer) and staining pattern, which may provide additional diagnostic insight.

ANA testing is commonly used as an initial screening tool for systemic autoimmune diseases.

Disease-Specific Autoantibodies

• DNA (ds) Antibody: Often associated with systemic lupus erythematosus and may correlate with disease activity.

• Sjogren’s Antibodies (SS-A/Ro and SS-B/La): Associated with Sjögren’s syndrome and sometimes lupus.

• Scl-70 Antibody (Topoisomerase I): Associated with systemic sclerosis.

• RNP Antibodies: Often associated with mixed connective tissue disease.

• Sm (Smith) Antibodies: Highly specific for systemic lupus erythematosus.

These markers help differentiate among connective tissue diseases.

Complement Components

• Complement C3 and C4: Proteins involved in immune complex processing. Low levels may indicate immune activation or consumption.

• CH50 (Total Complement Activity): Assesses overall complement pathway function.

Complement testing helps evaluate immune system activity and inflammatory burden.

Rheumatoid Factor (RF)

Rheumatoid Factor is an antibody commonly associated with rheumatoid arthritis and other inflammatory conditions. While not disease-specific, it contributes to the overall autoimmune assessment.

Together, these biomarkers provide a comprehensive evaluation of immune system activity and connective tissue disease–associated antibodies.

How Patients and Healthcare Providers Use the Results

Supporting Diagnosis of Autoimmune Disorders

Healthcare providers interpret panel results in combination with clinical symptoms, medical history, and physical examination findings. A positive ANA with specific antibody patterns may suggest the presence of a systemic autoimmune disorder. For example:

• Elevated dsDNA or Sm antibodies may support evaluation for systemic lupus erythematosus.

• Positive SS-A or SS-B antibodies may suggest Sjögren’s syndrome.

• Scl-70 antibodies may be associated with systemic sclerosis.

• RNP antibodies may be seen in mixed connective tissue disease.

• Positive Rheumatoid Factor may support evaluation for rheumatoid arthritis.

Laboratory findings alone do not establish a diagnosis, but they provide important diagnostic context.

Monitoring Disease Activity

In certain autoimmune conditions, trends in dsDNA antibodies or complement levels may correlate with changes in disease activity. Monitoring these markers can help healthcare providers assess immune system patterns over time.

Guiding Further Evaluation

Abnormal results may prompt additional diagnostic testing, imaging, or referral to a rheumatologist. Conversely, negative results may help narrow potential causes of symptoms and guide further clinical reasoning.

This panel serves as a structured laboratory foundation for evaluating systemic autoimmune processes and supporting evidence-based medical decision-making.

A Structured Approach to Autoimmune Evaluation

The Autoimmune Screening Panel provides a comprehensive and clinically relevant assessment of markers commonly associated with systemic autoimmune diseases. By combining ANA testing with disease-specific autoantibodies, complement components, and Rheumatoid Factor, this panel offers a broad yet focused evaluation of immune system activity.

Autoimmune conditions can be complex and multifaceted, often requiring thoughtful interpretation of laboratory findings in clinical context. This panel supports that process by organizing key biomarkers into a single, integrated assessment.

Through objective laboratory analysis and careful clinical interpretation, patients and healthcare providers can gain clearer insight into immune-related patterns, helping guide further evaluation, monitoring, and long-term management strategies based on measurable data.